Literature DB >> 16269968

Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial stiffness.

Mahmoud Zureik1, Jean-Louis Beaudeux, Dominique Courbon, Athanase Bénétos, Pierre Ducimetière.   

Abstract

BACKGROUND: The results of experimental studies have suggested that matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are involved in vascular remodeling. In a population-based study, we report the relationships of serum TIMP-1 with carotid intima-media thickness, carotid plaques and aortic arterial stiffness.
METHODS: Free health examinations were performed on 238 men free of coronary heart diseases (aged 56.5 +/- 10.4 years, 57.1% were hypertensive). Carotid-femoral pulse-wave velocity (PWV) was used to assess aortic stiffness. Carotid ultrasound examination included measurements (at sites free of plaques) of intima-media thickness (IMT) at the common carotid arteries (CCA) and assessment of atherosclerotic plaques in the extracranial carotid arteries.
RESULTS: The percentage of subjects with plaques was lower in subjects with low TIMP-1 values (P for trend = 0.0001). In multivariate analysis adjusted for age, body mass index, smoking habits, total cholesterol, triglycerides, C-reactive protein, heart rate, diabetes and systolic blood pressure, the odds ratio of carotid plaques in subjects with high values of TIMP-1 (tertile 3) compared to those with low values (tertile 1) was 2.89 (95% confidence interval 1.12-7.47, P < 0.01). TIMP-1 was positively associated with CCA-IMT and PWV in univariate analysis. However, the associations disappeared once age and systolic blood pressure were taken into account in the multivariate analysis.
CONCLUSION: This study shows that there is a differential association of TIMP-1 with PWV, CCA-IMT and carotid plaques. Our results suggest that TIMP-1 might be involved in plaque formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269968

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

2.  Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness.

Authors:  Maged Abdelnaseer; Nervana Elfayomi; Eman H Esmail; Manal M Kamal; Ahmed Hamdy; Rasha M Abdel Samie; Enji Elsawy
Journal:  Neurol Sci       Date:  2015-08-30       Impact factor: 3.307

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

5.  Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.

Authors:  Min Cheng; Satwat Hashmi; Xiaobo Mao; Qiu Tang Zeng
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

6.  Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study.

Authors:  Vijay Nambi; Alanna C Morrison; Ron C Hoogeveen; Josef Coresh; Shawn Miles; Charles Etta Rhodes; A Richey Sharrett; B Eric Boerwinkle; Christie M Ballantyne
Journal:  Tex Heart Inst J       Date:  2008

7.  Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells.

Authors:  Kalliopi Zafeiropoulou; Theodora Bita; Apostolos Polykratis; Stella Karabina; John Vlachojannis; Panagiotis Katsoris
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

8.  Heart diastolic dysfunction in patients with systemic sclerosis.

Authors:  Michał Ciurzyński; Piotr Bienias; Katarzyna Irzyk; Maciej Kostrubiec; Agnieszka Szewczyk; Urszula Demkow; Maria Siwicka; Katarzyna Kurnicka; Barbara Lichodziejewska; Piotr Pruszczyk
Journal:  Arch Med Sci       Date:  2014-06-27       Impact factor: 3.318

9.  Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.

Authors:  Stijn A Peeters; Lian Engelen; Jacqueline Buijs; Nish Chaturvedi; John H Fuller; Anders Jorsal; Hans-Henrik Parving; Lise Tarnow; Simone Theilade; Peter Rossing; Casper G Schalkwijk; Coen D A Stehouwer
Journal:  Cardiovasc Diabetol       Date:  2017-10-25       Impact factor: 9.951

10.  The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis.

Authors:  Zeneng Wang; Jennie Hazen; Xun Jia; Elin Org; Yongzhong Zhao; Lucas J Osborn; Nisreen Nimer; Jennifer Buffa; Miranda K Culley; Daniel Krajcik; Bert-Jan H van den Born; Koos Zwinderman; Bruce S Levison; Max Nieuwdorp; Aldons J Lusis; Joseph A DiDonato; Stanley L Hazen
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.